A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study.
OBJECTIVE
INFLOW (INdacaterol eFfectiveness and utiLizatiOn in COPD: real World evaluation) was a prospective, noninterventional study assessing the effectiveness and safety of long-acting bronchodilators in patients with chronic obstructive pulmonary disease (COPD) from the Middle East, Asia, and South Africa.


METHODS
Patients newly prescribed or switched to indacaterol or other long-acting β2-agonist (LABA), or tiotropium (monotherapy or in combination) were evaluated over 6 months. The primary endpoint was the clinical COPD questionnaire overall score at the end of the study.


RESULTS
Data were analyzed from 1,710 patients (mean postbronchodilator forced expiratory volume in 1 second, 59% predicted) who received indacaterol (n=1,179), other LABA (n=68), tiotropium (n=271), indacaterol plus tiotropium (n=167), or other LABA plus tiotropium (n=25). Across treatments, clinical COPD questionnaire overall score improved from baseline by 0.81-1.26 points (all P<0.0001), 63%-84% of patients were satisfied/very satisfied, and physicians rated effectiveness as good/very good in 63%-80% of cases. The indacaterol inhaler was rated easy/very easy to use by the majority of patients, and physicians considered its use clearly understood by most patients. All treatments had acceptable tolerability.


CONCLUSIONS
In real life clinical practice across a diverse region, indacaterol and other long-acting bronchodilators improved health status and were well regarded by patients and physicians.
St Georges Hospital University Medical Center, Ashrafieh, Beirut, Lebanon.
Georges
G
Juvelekian
Chest Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Waleed
W
El-Sorougi
Division of Pulmonary and Critical Care, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Chaicharn
C
Pothirat
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia, Persahabatan Hospital, Jakarta Timur, Indonesia.
Faisal
F
Yunus
Department of Pulmonary Medicine, Philippine Heart Center, Quezon City, Philippines.
Teresita
T
De Guia
Linkou Chang Gun Memorial Hospital, Taoyuan Hsien, Taiwan, ROC.
Han-Pin
HP
Kuo
Novartis Healthcare Pvt Ltd, Rangareddy, Telangana, India.
Shalma
S
Basu Patnaik
Novartis Pharma AG, Basel, Switzerland.
Virginia
V
Pilipovic
D000280:Administration, Inhalation; D000328:Adult; D000349:Africa / Q000453:epidemiology; D000368:Aged; D001208:Asia / Q000453:epidemiology; D001993:Bronchodilator Agents / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D029424:Pulmonary Disease, Chronic Obstructive; D015363:Quinolones / Q000627:therapeutic use*; D000069447:Tiotropium Bromide / Q000627:therapeutic use*; D016896:Treatment Outcome
D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D007189:Indans; D015363:Quinolones; C510790:indacaterol; D000069447:Tiotropium Bromide
Asia; Middle East; chronic obstructive pulmonary disease; indacaterol; long-acting bronchodilator; noninterventional study